Latest updates on atopic dermatitis
DOI:
https://doi.org/10.66344/jpad.27.4.2017.1178References
Ardern-Jones MR, Flohr C, Reynolds NJ, Holden CA. Atopic Eczema. In: Griffiths CEM, Barker J, Bleiker T, Charmers R, Creamers D, Eds. Rook’s Textbook of Dermatology. 9th Edn. Oxford: Wiley-Blackwell; 2016. p 41.33-41.34.
Leung TN, Hon KL. Eczema therapeutics in children: what do the clinical trials say? Hong Kong Med J. 2015;21: 251–60.
Paton DM. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis. Drugs Today. 2017;53:239-45.
Bissionnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175:902-11.
Saporito RC, Cohen DJ. Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients. Case Rep Dermatol. 2016;8:179-84.
10Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76:736-43.
Tsianakas A, Luger TA, Radin A. Dupilumab treatment improves quality of life in adult patients with moderate to severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Br J Dermatol. 2017 (ahead of publication).
Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Exp Rev Clin Immunol. 2017;13:425-37.
Vakharia PP, Silverberg JI. Monoclonal antibodies for atopic dermatitis: Progress and potential. BioDrugs. 2017;31:409-22.
Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: End of the drought? J Allergy Clin Immunol. 2017;140:633-43.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
